N-(3-Chloropropyl)cytisine | 249906-75-0

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 羽扇豆生物碱
• 英文名称: N-(3-Chloropropyl)cytisine
• 英文别名: (1R,9S)-11-(3-chloropropyl)-7,11-diazatricyclo[7.3.1.02,7]trideca-2,4-dien-6-one
• CAS: 249906-75-0
• 化学式: C₁₄H₁₉ClN₂O
• 分子量: 266.771
• InChiKey: QHFBSNAHKKMMLN-NWDGAFQWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(3-Chloropropyl)cytisine 、 1-(2-糠酰)哌嗪 在 sodium carbonate 作用下， 以 乙腈 为溶剂， 反应 7.0h， 以58%的产率得到N-[3-(4-Furoylpiperazin-1-yl)propyl]cytisine
  参考文献：
  名称：

  Synthesis and preliminary pharmacological evaluation of some cytisine derivatives

  摘要：

  Thirty-one N-derivatives of cytisine were prepared in order to modify its pharmacological profile and to obtain compounds of potential therapeutic interest either at a peripheral or central level, particularly as nicotinic ligands with improved ability to cross the blood-brain barrier. Actually, with the introduction of different kinds of substituent on the basic nitrogen of cytisine a variety of activities were observed, both in vivo (analgesic, dopamine antagonism, antihypertensive, inhibition of stress-induced ulcers, antiinflammatory, protection from PAF-induced mortality, hypoglycemic) and in vitro (positive cardio-inotropic, beta-adrenergic antagonism, alpha(1)- and alpha(2)-antagonism, inhibition of PAF-induced platelet aggregation). Six randomly selected compounds were tested for the ability to recognize a central nicotinic receptor and four of them exhibited K-i values; In the range 30-163 nM. (C) 1999 Elsevier Science S.A. All rights reserved.

  DOI：

  10.1016/s0014-827x(99)00049-x
• 作为产物：
  描述：

  1-溴-3-氯丙烷 、 cytisine 以 丙酮 为溶剂， 反应 20.0h， 以48%的产率得到N-(3-Chloropropyl)cytisine
  参考文献：
  名称：

  Synthesis and preliminary pharmacological evaluation of some cytisine derivatives

  摘要：

  Thirty-one N-derivatives of cytisine were prepared in order to modify its pharmacological profile and to obtain compounds of potential therapeutic interest either at a peripheral or central level, particularly as nicotinic ligands with improved ability to cross the blood-brain barrier. Actually, with the introduction of different kinds of substituent on the basic nitrogen of cytisine a variety of activities were observed, both in vivo (analgesic, dopamine antagonism, antihypertensive, inhibition of stress-induced ulcers, antiinflammatory, protection from PAF-induced mortality, hypoglycemic) and in vitro (positive cardio-inotropic, beta-adrenergic antagonism, alpha(1)- and alpha(2)-antagonism, inhibition of PAF-induced platelet aggregation). Six randomly selected compounds were tested for the ability to recognize a central nicotinic receptor and four of them exhibited K-i values; In the range 30-163 nM. (C) 1999 Elsevier Science S.A. All rights reserved.

  DOI：

  10.1016/s0014-827x(99)00049-x

文献信息

• Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them
  申请人：Kozikowski Alan P.

  公开号：US20080132486A1

  公开（公告）日：2008-06-05

  One aspect of the present invention relates to heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. A second aspect of the invention relates to the use of a compound of the invention for modulation of a mammalian nicotinic acetylcholine receptor. The present invention also relates to the use of a compound of the invention for treating a mammal suffering from Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, obesity, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism or trichtillomania.

  本发明的一个方面涉及杂环化合物，其是乙酰胆碱受体的配体。本发明的第二个方面涉及使用本发明的化合物来调节哺乳动物的乙酰胆碱受体。本发明还涉及使用本发明的化合物来治疗患有阿尔茨海默病、帕金森病、运动障碍、抽动症、精神分裂症、注意力缺陷障碍、焦虑、疼痛、抑郁症、强迫症、化学物质滥用、酗酒、记忆力障碍、假性痴呆、甘瑟综合征、偏头痛疼痛、贪食症、肥胖症、月经前综合征或黄体酮期后综合征、烟草滥用、创伤后应激障碍、社交恐惧症、慢性疲劳综合征、早泄、勃起障碍、厌食症、睡眠障碍、自闭症、哑症或拔毛癖的哺乳动物。
• US8030300B2
  申请人：——

  公开号：US8030300B2

  公开（公告）日：2011-10-04